Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

The Rosen Law Firm Reminds Delcath Investors of Important Class Action Deadline -- DCTH

DCTH
The Rosen Law Firm Reminds Delcath Investors of Important Class Action Deadline -- DCTH

NEW YORK, June 5, 2013 (GLOBE NEWSWIRE) -- The Rosen Law Firm reminds investors of the July 8, 2013 deadline in the class action lawsuit filed on behalf of all purchasers of the securities of Delcath Systems, Inc., (Nasdaq:DCTH) between April 21, 2010 and May 2, 2013, inclusive.

To join the Delcath class action, go to the website at http://rosenlegal.com or call Phillip Kim, Esq. or Kevin Chan toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company's New Drug Application for Melblez Kit (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System), for the treatment of patients with unresectable ocular melanoma metastatic to the liver contained risks including substantial and severe toxicity and deaths associated with the drug's adverse reactions; and (2) the Company's manufacturing facilities were in violation of Current Good Manufacturing Practices. The lawsuit asserts that when this adverse information entered the market, the value of Delcath securities dropped, damaging investors.

A class action lawsuit has already been filed on behalf of Delcath shareholders. If you wish to serve as lead plaintiff, you must move the Court no later than July 8, 2013. If you wish to join the litigation or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm focuses on prosecuting securities class action litigation and actions involving financial fraud. The Rosen Law Firm represents investors throughout the globe concentrating its practice in securities class actions.

CONTACT: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan The Rosen Law Firm P.A. Tel: (212) 686-1060 Toll Free: 1-866-767-3653 Fax: (212) 202-3827 275 Madison Avenue, 34th Floor New York, New York 10016 lrosen@rosenlegal.com pkim@rosenlegal.com kchan@rosenlegal.com www.rosenlegal.com  


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today